luspatercept: Clinical Trials

34 trials of luspatercept, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 recruiting, 9 completed, 6 not yet recruiting, 4 active not recruiting. 34 Phase 2, 3 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 234Recruiting 12, Completed 9, Not yet recruiting 6, Active not recruiting 4, Suspended 1, Terminated 1, Unknown 1
Phase 13Recruiting 2, Suspended 1
Phase 32Not yet recruiting 2

Follow luspatercept: new trials by email Literature Review of luspatercept trials Research Report on luspatercept

Trials (filtered) newest first · largest first

All 34 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial)
Biospecimen Collection, Bone Marrow Aspiration, Emavusertib - Myelodysplastic Syndrome
Phase 2Not yet recruitingNational Cancer Institute (NCI)2702026-12-182026-09-22
Study of LusPACercept in Participants With Myelofibrosis Associated Anemia and Thrombocytopenia
Luspatercept, Pacritinib - Myelofibrosis
Phase 2Not yet recruitingCase Comprehensive Cancer Center502026-12-012026-11-13
Gecacitinib Plus Luspatercept in Patients With Myelofibrosis and Anemia
Gecacitinib, Luspatercept - Myelofibrosis
Phase 2Not yet recruitingPeking Union Medical College Hospital312026-11-012026-11-16
A Study of Luspatercept in People With Anemia
Luspatercept - Anemia, Chronic Kidney Disease
Phase 2RecruitingMemorial Sloan Kettering Cancer Center302026-07-202026-10-13
Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies
Luspatercept, Epoetin - Luspatercept, Epoetin
Phase 2 / Phase 3Not yet recruitingNanfang Hospital, Southern Medical University902026-06-152026-06-09
Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis
Luspatercept, Control - Luspatercept, Poor Erythroid Engraftment
Phase 2 / Phase 3Not yet recruitingNanfang Hospital, Southern Medical University1962026-05-012026-04-20
Luspatercept in Patients Affected With Rare Inherited Anemias
Reblozyl - Hereditary Red Blood Cell Disorder (Disorder)
Phase 2RecruitingEuroBloodNet Association452026-03-172026-11-17
The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCT
Luspatercept - HSCT
Phase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China202026-03-142026-03-04
Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients
Luspatercept combined with low-dose thalidomide, Luspatercept plus placebo - Transfusion-dependent β-thalassemia Patients
Phase 2RecruitingRongrong Liu782026-02-012026-01-13
Luspatercept + Darbepoetin in MDS
Luspatercept, Darbeopoetin - MDS (Myelodysplastic Syndrome)
Phase 2RecruitingYale University602025-12-162026-09-14
Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT)
Luspatercept - Acute Leukemia
Phase 1 / Phase 2RecruitingZhujiang Hospital462025-10-012026-01-23
Luspatercept for Clonal Cytopenias of Uncertain Significance
Luspatercept - CCUS Clonal Cytopenia of Undetermined Significance, Anemia
Phase 2RecruitingWeill Medical College of Cornell University502025-03-252026-03-24
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Momelotinib, Luspatercept - Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Phase 2RecruitingGlaxoSmithKline682025-02-282026-11-04
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Phase 2RecruitingNational Cancer Institute (NCI)20002024-06-182026-11-02
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
Luspatercept - Myelodysplastic Syndromes
Phase 2Active not recruitingM.D. Anderson Cancer Center102024-03-012026-06-22
The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes
Luspatercept - Lower Risk MDS Per IPSS-R
Phase 2UnknownInstitute of Hematology & Blood Diseases Hospital, China362023-07-012024-03-12
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
Luspatercept - Myelodysplastic Syndromes, Myeloproliferative Neoplasm
Phase 2Active not recruitingH. Lee Moffitt Cancer Center and Research Institute62023-02-212026-05-05
Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified
Phase 2TerminatedMayo Clinic32023-02-202024-09-19
Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia
Luspatercept, Cyclosporine - Aplastic Anemia
Phase 2CompletedBing Han582022-12-192025-09-16
A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia
Luspatercept, Placebo - Anemia
Phase 2Active not recruitingBristol-Myers Squibb1892022-12-092026-09-10

Showing 20 of 34. Sign in to see all of them.

Conditions studied

Myelodysplastic Syndromes (12)  ·  Anemia (11)  ·  Primary Myelofibrosis (5)  ·  beta-Thalassemia (4)  ·  Myeloproliferative Disorders (3)  ·  Hematologic Neoplasms (2)  ·  Thrombocytopenia (2)  ·  Anemia, Aplastic (1)  ·  Anemia, Refractory, with Excess of Blasts (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Leukopenia (1)  ·  Neutropenia (1)  ·  Renal Insufficiency, Chronic (1)  ·  Thalassemia (1)  ·  Thrombocytosis (1)

Sponsors

Celgene (5)  ·  Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (4)  ·  Bristol-Myers Squibb (2)  ·  Institute of Hematology & Blood Diseases Hospital, China (2)  ·  Nanfang Hospital, Southern Medical University (2)  ·  National Cancer Institute (NCI) (2)  ·  Associazione Qol-one (1)  ·  Bing Han (1)  ·  Case Comprehensive Cancer Center (1)  ·  EuroBloodNet Association (1)  ·  GlaxoSmithKline (1)  ·  Groupe Francophone des Myelodysplasies (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  M.D. Anderson Cancer Center (1)  ·  Mayo Clinic (1)

Countries

United States (13)  ·  China (10)  ·  Italy (10)  ·  Germany (5)  ·  Greece (5)  ·  France (4)  ·  Thailand (3)  ·  Canada (2)  ·  Japan (2)  ·  Lebanon (2)  ·  Turkey (Türkiye) (2)  ·  United Kingdom (2)  ·  Hong Kong (1)  ·  India (1)  ·  Malaysia (1)

Top investigators

Qifa Liu (2)  ·  Abhishek A. Mangaonkar, M.B.B.S. (1)  ·  Akriti Jain, MD, FACP (1)  ·  Anne Sophie Kubasch, Dr. (1)  ·  Guillermo Garcia-Manero, M D (1)  ·  Jeevan Shetty, MD (1)  ·  Jerald P Radich (1)  ·  Maximilian Stahl, MD (1)  ·  Mikkael Sekeres, MD (1)  ·  Pinkal Desai, MD (1)  ·  Rami Komrokji, MD (1)  ·  Rena J Buckstein (1)

Results publications

PMID 28870615, PMID 30617198, PMID 35998303, PMID 36505885, PMID 20424252, PMID 28096091, PMID 29895954, PMID 33570654, PMID 34002031, PMID 36007538, PMID 36902217, PMID 36948565, PMID 37311468, PMID 37345627, PMID 37606495, PMID 37704579, PMID 38820422, PMID 39991012, PMID 40875596, PMID 41857682, PMID 42057135

NIH funding

2014 (2), 2015 (1), 2017 (1), U10CA180863 (1), U10CA180888 (1)